Skip to main content
TipRanks
Go Ultimate75% OFF

Nuvectis Pharma (NVCT) Stock Price & Analysis

141 Followers

NVCT Stock Chart & Stats

$20.29$1.09(5.68%)
At close: 4:00 PM EST
$17.5$20$22.5$25Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$18.65 - $20.37
52-Week Range
$5.77 - $29.28
Previous Close
$19.20
Volume
N/A
Average Volume (3M)
200.75K
Market Cap
$697.75M
Enterprise Value
$481.63M
Total Cash (Recent Filing)
$140.71M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
0.13
Next Earnings
Mar 09, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

Zero reported debt reduces solvency pressure and preserves flexibility while the company advances clinical programs. The move from negative equity in 2021 to substantial positive equity and assets also provides a stronger financial base for development spending over the next several quarters.

Extended Cash Runway

A stated cash runway into the second half of 2029 gives Nuvectis time to pursue regulatory filings, trials, and pipeline development without relying immediately on operating revenue. This supports continuity of execution across several planned clinical and regulatory milestones.

Validated Late-stage Pipeline

China approval for NXP-100 and encouraging NXP-200 response data materially strengthen the pipeline beyond an entirely early-stage profile. These assets offer multiple potential development and commercialization paths across PNH, kidney disease, glioma, and other solid tumors.

Bears Say

Pre-revenue Business Model

The absence of reported revenue means Nuvectis has not yet demonstrated commercial traction or operating leverage. Until a candidate reaches the market and generates sales, the company must fund development through its balance sheet and external capital rather than internally generated business cash.

Widening Losses And Cash Burn

Rising losses and sustained negative operating and free cash flow increase the resources required to advance the pipeline. Even with current liquidity, continued spending without revenue raises the likelihood that future development may require additional financing or tighter capital allocation.

Unresolved U.S. Regulatory Path

Uncertainty over the U.S. development requirements could extend timelines, increase clinical costs, and delay access to a major market for NXP-100. The need for one or more additional studies would also consume capital and create execution risk despite constructive FDA discussions.

Nuvectis Pharma News

NVCT FAQ

What was Nuvectis Pharma’s price range in the past 12 months?
Nuvectis Pharma lowest stock price was $5.77 and its highest was $29.28 in the past 12 months.
What is Nuvectis Pharma’s market cap?
Nuvectis Pharma’s market cap is $697.75M.
When is Nuvectis Pharma’s upcoming earnings report date?
Nuvectis Pharma’s next earnings report is estimated for Mar 09, 2027 (not yet confirmed), which is in 110 days.
How were Nuvectis Pharma’s earnings last quarter?
Nuvectis Pharma released its earnings results on Nov 04, 2026. The company reported -$1.02 earnings per share for the quarter, missing the consensus estimate of -$0.242 by -$0.778.
Is Nuvectis Pharma overvalued?
According to Wall Street analysts Nuvectis Pharma’s price is currently Undervalued.
Does Nuvectis Pharma pay dividends?
Nuvectis Pharma does not currently pay dividends.
What is Nuvectis Pharma’s EPS estimate?
Nuvectis Pharma’s EPS estimate is -0.37.
How many shares outstanding does Nuvectis Pharma have?
Nuvectis Pharma has 34,388,910 shares outstanding.
What happened to Nuvectis Pharma’s price movement after its last earnings report?
Nuvectis Pharma reported an EPS of -$1.02 in its last earnings report, missing expectations of -$0.242. Following the earnings report the stock price went down -4.498%.
Which hedge fund is a major shareholder of Nuvectis Pharma?
Hedge funds hold Nuvectis Pharma shares: the largest hedge-fund position in Nuvectis Pharma is 72,325,987 shares, and hedge funds increased their holdings by 1.2M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology